| Revenue | $403M (Q3) vs. $502M (Q2) | CFO |
| Adjusted EBITDA | $41M (Q3) vs. $79M (Q2) | CFO |
| Adjusted EBITDA margin | 10% (Q3) vs. 16% (Q2) | CFO |
| Free cash flow | -$29M (Q3) vs. +$54M (Q2) | CFO |
| Stimulation Services revenue | $343M (Q3) vs. $432M (Q2) | CFO |
| Stimulation Services EBITDA | $20M (Q3) vs. $51M (Q2) | CFO |
| Proppant Production revenue | $76M (Q3) vs. $78M (Q2) | CFO |
| Proppant Production EBITDA | $8M (Q3) vs. $15M (Q2) | CFO |
| Manufacturing revenue | $48M (Q3) vs. $56M (Q2) | CFO |
| Manufacturing EBITDA | $4M (Q3) vs. $7M (Q2) | CFO |
| SG&A | $43M (Q3) vs. $51M (Q2) | CFO |
| Cash CapEx | $38M (Q3) vs. $43M (Q2) | CFO |
| Total cash & equivalents | ~$58M (Sep 30, 2025) | CFO |
| Total liquidity | ~$95M (Sep 30, 2025) | CFO |
| ABL borrowings | $160M (Sep 30, 2025) | CFO |
| Total debt outstanding | ~$1.1B (Sep 30, 2025) | CFO |
| Long-term debt repaid in Q3 | ~$32M | CFO |
| Equity raise net proceeds | ~$79M (August) | CFO |
| Flotek seller note sale | $40M (Nov 7) | CEO |
| 2025 CapEx guidance | $160M–$190M | CFO |
| Cost savings target | $100M annualized by Q2 2026 | CEO, CFO |